December 27, 2017 / 7:02 AM / 8 months ago

BRIEF-Elanix's Partner Transwell Biotech Completes Phase I Of Phase I/Ii Clinical Trial With Progenitor Cell Treatment For Skin Graft Wounds

Dec 27 (Reuters) - ELANIX BIOTECHNOLOGIES AG:

* DGAP-NEWS: ELANIX’S PARTNER TRANSWELL BIOTECH COMPLETES PHASE I OF PHASE I/II CLINICAL TRIAL WITH PROGENITOR CELL TREATMENT FOR SKIN GRAFT WOUNDS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below